Big Pharma Sharma's Bullets: (Over)reacting to Recent Industry News

Some thoughts and analyses on recent news that piqued my interest

Jan 31, 2024

∙ Paid

man sitting on chair holding newspaper on fire — Photo by Nijwam Swargiary on Unsplash

Intro

It's been another busy week in the world of biopharma! From promising clinical trial results to interesting deals, there's been no shortage of big news. In this week's post, I'll be rapid firing through some of the stories that caught my eye and providing my quick takes on each one.

Without further ado, let’s get into it!

Gilead deepens its investment in Arcus and making TIGIT successful

Summary of what happened (Links: PR | Slides)

Gilead will make an additional equity investment of $320 million in Arcus to bring its total ownership to 33%. This pushes Arcus’ runway out to 2027
The companies are reprioritizing development of domvanalimab (anti-TIGIT mAb) and accelerating development of its P3 studies in NSCLC (STAR-121) and GI cancers (STAR-221) and launching a new P3 study (STAR-131) in NSCLC
The P3 ARC-10 study (domvanalimab + zimberelimab (PD-1) in 1L PD-L1-high NSCLC, will be discontinued
Gilead is giving back full control of the P3 1L study of CD73 inhibitor ( quemliclustat) to Arcus
If you’re new to Big Pharma Sharma and want to read more of my content, subscribe below and get 1-week free! After that, if you’d like to keep going, it’s <$10/month! Join many of your colleagues who are getting smarter each week, with BioPharma Industry analysis from an insider’s perspective.
By the way, I'm in the process of sourcing sponsors for future posts in 2024. These posts would be 100% accessible to all subscriber levels and get your brand, product, or service in front of my audience of BioPharma Industry decision-makers. If you're interested in becoming a Big Pharma Sharma sponsor, please reach out to me here or on my socials. You can learn more about sponsored posts on the Sponsored Posts page (link).

Keep reading with a 7-day free trial

Subscribe to Big Pharma Sharma to keep reading this post and get 7 days of free access to the full post archives.